Last reviewed · How we verify
NCT05764993
Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention
Phase 2 trial testing CUVITRU - Ig subcutaneous human 20% in COPD Exacerbation Acute in 40 participants. Status unknown.
28 February 2025
Quick facts
| Lead sponsor | Rochester General Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 1 June 2023 |
| Primary completion | 28 February 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- CUVITRU - Ig subcutaneous human 20% — full drug profile →
- Standard Medical Therapy — full drug profile →
Conditions studied
- COPD Exacerbation Acute — all drugs for COPD Exacerbation Acute →
Sponsor
Rochester General Hospital
Who can join
Adults 18 to 82, any sex, with COPD Exacerbation Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To examine the prevalence of humoral immunodeficiency in patients with Chronic Obstructive Pulmonary disease (COPD) by evaluating both immunoglobulin levels and vaccine responses. Patients with COPD and humoral dysfunction will be offered treatment with Subcutaneous Immune Globulin Replacement Therapy (SCIgR) in an attempt to decrease future AECOPD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05764993
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COPD Exacerbation Acute
Currently open trials in the same condition.
- NCT05703919 — Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease · Phase 4 · recruiting
- NCT06274957 — The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation · NA · recruiting
- NCT06331416 — Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation · NA · recruiting
- NCT05452226 — Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia · NA · recruiting
- NCT05568043 — The Reducing REVISITS Study: A Cluster RCT · NA · recruiting
Other Rochester General Hospital trials
Trials by the same sponsor.
- NCT03730129 — Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig · Phase 2, PHASE3 · completed
- NCT03595488 — Dupilumab for Aspirin-exacerbated Respiratory Disease · Phase 2 · completed
- NCT02341209 — Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma · Phase 2 · terminated
- NCT03211065 — Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig · Phase 2, PHASE3 · completed
- NCT03200093 — Oral Vancomycin for Preventing Clostridium Difficile Recurrence · Phase 4 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05764993 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rochester General Hospital
- Last refreshed: 15 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05764993.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing